Calgary, Alberta, 8. April 2021 Hemostemix Inc. („Hemostemix“Or the “Companies“) (TSXV:HEM, OTC: HMTXF, Frankfurt: 2VFO.F) is pleased to announce that the company is listed on the Frankfurt Stock Exchange under the symbol 2VFO.F and HE Capital Markets Ltd. (HE Capital) with the development and implementation of a North American and European multimedia digital advertising campaign on certain investor-oriented and financial market-oriented websites. In addition, HE Capital will offer additional media communication services to strengthen the company’s profile in North America and Europe as a whole.
Thomas Smeenk, CEO, said: “With the listing in Frankfurt and the commissioning of HE Capital, we are deepening our liquidity pools and increasing the number Hemostemix to a wider investment community. In the US we are working on the company to list, and we are exploring how to best reach our audiences in Asia, ”said Smeenk.
The cash compensation the company pays for these services includes USD18,000 for an initial three month campaign. HE Capital acts independently of Hemostemix and currently has no direct or indirect interest in the company or its securities. HE Capital may choose to sell in the future Hemostemix to acquire.
HE Capital is a London-based investor relations and capital markets consultancy, the Offers customers of listed companies in North America and Europe comprehensive communication solutions through a combination of investor relations, public relations and digital and social media. HE Capital’s business address is 6 Hays Lane, London Bridge, London, SE1 2HB, United Kingdom.
Hemostemix is a publicly traded company for autologous stem cell therapies. As the winner of the World Economic Forum Technology Pioneer Award, the company developed and markets its lead product ACP-01 for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and others Ischemic diseases. ACP-01 has been used to treat over 300 patients and is the subject of a randomized, placebokontrollierten, double-blind study of safety and efficacy in patients with advanced critical Limb ischemiawho have exhausted all other options to save their limbs from amputation.
On October 21, 2019 gave the company the results of its randomized, double-blind, placebokontrollierten clinical phase II study with ACP-01 to the critical Limb ischemia in an abstract “Autologous Stem Cell Treatment for CLI Patients with No Revaskularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup“Which reported that 83% of patients healed ulcers and relieved ischemic resting pain, with results sustained for up to 4.5 years.
The Companies owns 91 Patent in five Patent families of the title: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage und Automated Cell Therapy. For more information, see www.hemostemix.com.
Contact: Thomas Smeenk, President, CEO & Co-Founder
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. All statements contained herein that are not historical facts are forward-looking information. In particular, this press release contains forward-looking information regarding the financing of Hemostemix, the settlement of trade accounts payable with shares. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects current estimates by Hemostemix reflect and are based on information that Hemostemix are currently available, as well as on assumptions that Hemostemix deems appropriate. These assumptions include, but are not limited to: The underlying value of Hemostemix and its common stock; the successful resolution of the litigation that Hemostemix prosecute or defend (the “Litigation”); when the full clinical trial data was received; the results of ACP-01 research, studies and tests that are equivalent to or better than previous research, studies and tests, and management’s expectations of the expected results; that the general and administrative costs of Hemostemix stay constant; the receipt of all necessary governmental approvals for research, experiments or studies as well as the disclosed or required or desired funding from Hemostemixincluding acceptance of the TSX Venture Exchange and third party consent; the level of activity, market uptake and market trends in the healthcare sector; the economy in general; the interest of consumers in the services and products of Hemostemix; the competition and the competitive advantages of Hemostemix; and obtaining satisfactory funding to finance the operation of Hemostemix, including research, trials or studies, as well as litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause the actual results, activities, performance or achievements of the company to be affected Hemostemix materially differ from those expressed or implied in this forward-looking information. Such risks and other factors could include the ability of Hemostemixto complete the current CLI clinical trial, a satisfactory one Futility-Perform analysis and the results of this and future clinical studies; Litigation and potential litigation with whom Hemostemix could be faced; general business, economic, competitive, political, and social uncertainties; general capital market conditions and market prices for securities; Delay or failure to grant approvals by bodies or authorities; the actual results of future surgery, including the actual results of any future research, experiment, or study; Competition; Changes in legislation that Hemostemix affect; the timing and availability of external funding on acceptable terms; long-term capital requirements and future developments in the markets of Hemostemix and the markets in which the company intends to compete; Lack of skilled, skilled labor or loss of key people; and risks associated with the COVID-19 pandemic, including various recommendations, orders and actions by government agencies to try to contain the pandemic, including travel restrictions, border closings, closings of non-essential businesses, interruptions to services, quarantines, self-isolation, shelters and social distancing, disruptions in markets, disruptions in economic activity and financing, disruptions in supply chains and distribution channels, and deterioration in general economic conditions, including a possible national or global recession or depression; the potential impact of the COVID-19 pandemic Hemostemix, including lower demand for those from Hemostemix services offered; and a deterioration in financial markets affecting the ability of Hemostemix could restrict obtaining external funding. For a description of other risk factors that could cause actual results to differ materially from the forward-looking information, see the disclosure documents of Hemostemix on the SEDAR website at www.sedar.com. Although Hemostemix Has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that could cause results not to be as expected, estimated or intended. Readers are cautioned that the above list of factors is not exhaustive. Readers are cautioned not to place undue reliance on forward-looking information, as there can be no assurance that the plans, intentions or expectations on which they are based will materialize. The forward-looking information contained in this press release is expressly addressed by this precaution limited. The forward-looking information contained in this press release represents the expectations of Hemostemix at the time of this press release and are subject to change after that date. Hemostemix however, expressly disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or for other reasons, unless this is expressly required under applicable securities law.
The source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding. The German version can be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the translator’s point of view, the message does not constitute a buy or sell recommendation! Please note the original English message on www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company website!